ClinicalTrials.gg
CompletedNCT00134693Updated Jul 31, 2017

A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis

A Phase 2 interventional study of Prednisolone and SB-681323 in Arthritis, Rheumatoid, sponsored by GlaxoSmithKline. Completed at 28 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-31.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · GlaxoSmithKline.

Enrollment
17th of 40
77 · median 52
Started
2005
with 7 others
Phase 2
17 of 44
none open now
Registered
4th of 44
by date

Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, this one is the 17th largest by enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2005, is one of 17 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is designed to compare a range of doses of SB-681323 with prednisolone, which has known effects on rheumatoid arthritis patients. By comparing the two drugs and their effects on blood proteins that indicate for rheumatoid arthritis, we hope to ascertain information on the most effective dose of SB-681323 to use in future.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • SB-681323 rheumatoid arthritis CRP biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology.
  • Must have 3 or more swollen or 3 or more tender/painful joints at screening.
  • Must be on stable weekly methotrexate (2.5mg - 25mg) for at least eight weeks prior to screening.

Exclusion criteria

Exclusion criteria:

  • Must not be morbidly obese.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
77 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Analysis for C-Reactive protein (CRP) levels 72 hours post-dose following SB-681323

    CRP levels were compared between SB-681323 and placebo 72 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.

    Time frame: Day 3 (at 72 hour)

Secondary outcomes

  1. Analysis of CRP levels 24 and 48 hours post-dose following SB-681323

    CRP levels were compared between SB-681323 and placebo 24 and 48 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.

    Time frame: Day 1 (at 24 hour) and Day 2 (at 48 hour)

  2. Analysis of Interleukin (IL)-6 levels up to 72 hours post-dose following SB-681323

    A blood sample of approximately 5 milliliter (mL) was taken for measurement of serum markers. IL-6 measurements were performed at 1 hour, 3, hours, 24 hours and 72 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.

    Time frame: Upto Day 3 (at 1, 3, 24 and 72 hour)

  3. Number of participants with adverse events (AE) and serious adverse events (SAE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. There were no SAEs reported in this study.

    Time frame: Upto Day 3 (72 hours)

  4. Change from Baseline in vital sign systolic blood pressure (SBP) and diastolic blood pressure (DBP)

    Supine vital signs SBP and DBP were recorded whilst the participant was in a supine position (participant lying flat with maximum one pillow) having rested in that position for at least 10 minutes before each reading. Measurements were performed at 90 minutes, 3 hours, 24 hours and 72 hours post-dose. Baseline was defined as assessment performed pre-dose at Day 0. Change from Baseline was calculated by subtracting the Baseline value from the individual post-randomization values at the time of assessment.

    Time frame: Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)

  5. Change from Baseline in vital sign heart rate

    Supine vital signs (heart rate) was recorded whilst the participant was in a supine position (participant lying flat with maximum one pillow) having rested in that position for at least 10 minutes before each reading. Measurements were performed at 90 minutes, 3 hours, 24 hours and 72 hours post-dose. Baseline was defined as assessment performed pre-dose at Day 0. Change from Baseline was calculated by subtracting the Baseline value from the individual post-randomization values at the time of assessment.

    Time frame: Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)

  6. Number of participants with abnormal electrocardiogram (ECG) findings

    Full 12-lead ECGs were recorded using an ECG machine that automatically calculated the pulse rate and measured PR, RR, QRS, QT, QTc(b) intervals (Bazett's correction was applied to QTc measurements). Measurements were carried out at pre-dose, 1 hour and 3 hours on Day 1. ECG findings were characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS). Data has been presented for A-NCS findings on Day 1.

    Time frame: Day 1 (pre-dose, 1 hour and 3 hour)

  7. Number of participants with clinical chemistry data outside the clinical concern range

    Clinical chemistry parameters included albumin, alkaline phosphatase, alanine amino transferase, indirect bilirubin, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, potassium, lactate dehydrogenase, triglycerides. Measurements were carried out at pre-dose, 24 hours, 48 hours and 72 hours. Data for number of participants with values outside clinical concern range defined as high and low have been presented.

    Time frame: Upto Day 3 (pre-dose, 24, 48 and 72 hours

  8. Number of participants with hematology data outside the clinical concern

    Hematology parameters included eosinophils, hemoglobin, hematocrit, lymphocytes, mean corpuscle hemoglobin, mean corpuscle volume, platelet count, reticulocytes, white blood cell count (WBC). Measurements were carried out at pre-dose, 24 hours and 72 hours. Data for number of participants with values outside clinical concern range defined as high and low have been presented.

    Time frame: Upto Day 3 (pre-dose, 24 and 72 hours)

  9. Number of participants with abnormal urinalysis dipstick results

    Approximately 10-20 mL mid-stream urine was collected into a sterile container and was screened by dipstick for: occult blood, proteins, ketones, glucose, red blood cells (RBC) and WBC. Sediment microscopy was performed only if any of the Multi-stick tests were abnormal. In such cases, microscopy was performed for: WBC, RBC, hyaline casts, granular casts, cellular casts. Data for number of participants with abnormal urinalysis results for positive parameters as assessed by dipstick and microscopic analysis have been presented.

    Time frame: Upto Day 3 (pre-dose, 24 and 72 hours)

  10. Whole blood messenger RNA (mRNA) levels of tumor necrosis factor alpha [TNF-α], IL-8, IL-1β and Cyclo-oxygenase-2 [COX-2] (and other genes implicated in the pathogenesis of RA or genes involved in the mode of action of the compounds administered)

    Blood samples were taken for extraction of whole blood mRNA (2 x 2.5mL PAXgene tubes). The samples were taken at the time-points pre-dose, 45 minutes, 90 minutes and 3 hours. Messenger RNA levels for various markers was measured. These markers included Prednisolone markers: DDIT4, DUSP1, FKBP5, GILZ, IL1R2, TXNIP, ZNF145 and p38 markers: COX2, IFI30, IL1b, IL6, IL8, TNF. An aliquot of mRNA was stored for later analysis of other genes associated with the pathogenesis of RA and in the mode of action of the compounds administered.

    Time frame: Pre-dose, 45 minutes, 90 minutes and 3 hours on Day 1

07

Study locations

28 sites
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Douglas, Queensland 4814, Australia
  • GSK Investigational Site
    Woolloongabba, Queensland 4102, Australia
  • GSK Investigational Site
    Daw Park, South Australia 5041, Australia
  • GSK Investigational Site
    Woodville, South Australia 5011, Australia
  • GSK Investigational Site
    Hobart, Tasmania 7000, Australia
  • GSK Investigational Site
    Shenton Park, Western Australia 6008, Australia
  • GSK Investigational Site
    Amiens, Picardie 80054, France
  • GSK Investigational Site
    Montpellier Cedex 5, 34295, France
  • GSK Investigational Site
    Villingen-Schwenningen, Baden-Wuerttemberg 78054, Germany
  • GSK Investigational Site
    Hildesheim, Niedersachsen 31134, Germany
  • GSK Investigational Site
    Chemnitz, Sachsen 09111, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04107, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04229, Germany
  • GSK Investigational Site
    Berlin, 12163, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Berlin, 14059, Germany
  • GSK Investigational Site
    Berlin, 14109, Germany
  • GSK Investigational Site
    Ekaterinburg, 620102, Russian Federation
  • GSK Investigational Site
    Moscow, 115522, Russian Federation
  • GSK Investigational Site
    Ryazan, 390026, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150003, Russian Federation
  • GSK Investigational Site
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • GSK Investigational Site
    Wigan, Lancashire WN6 9EP, United Kingdom
  • GSK Investigational Site
    Liverpool, Merseyside L9 7AL, United Kingdom
  • GSK Investigational Site
    Newcastle, Northumberland NE1 4LP, United Kingdom
  • GSK Investigational Site
    Oxford, OX3 7LP, United Kingdom
  • GSK Investigational Site
    Sheffield, S10 2RX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2005 to primary completion in Aug 2006, 13 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 13 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2005
First posted
Aug 25, 2005
StartActual
Jun 21, 2005
Primary completionActual
Aug 3, 2006
CompletionActual
Aug 3, 2006
Last update
Jul 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00134693
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 25, 2005
Start date
Jun 21, 2005
Primary completion
Aug 3, 2006
Completion
Aug 3, 2006
Last update
Jul 31, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisolone · Dilmapimod

Start the discussion